Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Rep. Ro Khanna (D-Calif.) joins 'Squawk Box' to discuss President Trump's third week back in office, DOGE and Elon Musk's efforts to downsize the federal government, working across the aisle in the ...

We expect Lilly to continue to grow faster than the market, and model 60% 2025 Lilly GLP-1 sales growth. Lilly gained 5 points in US prescription share in 2024, and Zepbound’s 56% share of new ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of ...

Eli Lilly posts robust Q4 earnings as Mounjaro and Zepbound sales more than double, lifting full-year revenue by 32% ...

The company predicted operating profit for 2025 to climb between 19% and 27%, compared to growth of 26% last year.

Highlights,Institutional holdings in Eli Lilly (NYSE:LLY) continue to expand, with significant new positions added.,Geode ...

Since joining Lilly in 2022, Winselow has served as Group Vice President and Chief Commercial Officer of Lilly Oncology.

Dow, S&P 500, and Nasdaq futures are also falling in premarket trading Monday as the stock market digests Donald Trump's latest tariffs moves.